Trade and other receivables |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Trade and other receivables | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Trade and other receivables | 15Trade and other receivables
Included within R&D tax relief receivable is £nil thousand claimed under the HMRC RDEC scheme (2024: £8,686 thousand) and £16,644 thousand for R&D tax relief claimed under the HMRC ERIS and predecessor schemes (2024: £nil). See note 8 for further information in respect of the reversal tax relief previously recognized under HMRC RDEC scheme. Expected credit losses were not significant in 2025 or 2024. The Group’s exposure to credit and market risks, including impairments and allowances for credit losses, relating to trade and other receivables is disclosed in note 26. |